Bortezomib for refractory antibody-mediated cardiac allograft rejection.

Peter M Eckman, Marit Thorsgard, David H Maurer, Youngki Kim, Rita R. Alloway, E. Steve Woodle

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.

Original languageEnglish (US)
Pages (from-to)475-478
Number of pages4
JournalClinical transplants
StatePublished - 2009


Dive into the research topics of 'Bortezomib for refractory antibody-mediated cardiac allograft rejection.'. Together they form a unique fingerprint.

Cite this